Recent Advances in the Medical Management of Early Pregnancy Loss

AbstractPurpose of ReviewTo provide an update on advances in medical management of early pregnancy loss, including the addition of mifepristone pretreatment to existing regimens.Recent FindingsThe utilization of misoprostol for medical management of early pregnancy loss has been studied extensively and is established as a safe and effective treatment. Two recent randomized controlled trials have demonstrated that the addition of mifepristone pretreatment significantly increases the effectiveness of misoprostol and a large body of data demonstrate the excellent safety profile of mifepristone. However, the Food and Drug Administration Risk Evaluation and Mitigation Strategy restrictions impose a major barrier to mifepristone use.SummaryThe addition of mifepristone to existing misoprostol regimens has significantly improved the effectiveness and patient-centered benefits of medical management of early pregnancy loss. Mifepristone restrictions need to be removed in order to decrease the barriers to women obtaining evidence-based care.
Source: Current Obstetrics and Gynecology Reports - Category: OBGYN Source Type: research